Description
Latin name
EMOXIPIN
Release form
Emoxipine. Injection.
Packing
10 ampoules of 1 ml.
Pharmacological action
Angioprotector, reduces the permeability of the vascular wall, is an inhibitor of free radical processes, antihypoxant and antioxidant.
Reduces blood viscosity and platelet aggregation, increases the content of cyclic nucleotides (cAMP and cGMP) in platelets and brain tissue, has fibrinolytic activity, reduces the permeability of the vascular wall and the risk of hemorrhage, promotes their resorption. Expands coronary vessels, in the acute period of myocardial infarction limits the size of the focus of necrosis, improves the contractility of the heart and the function of its conducting system. With increased blood pressure has a hypotensive effect. In acute ischemic disorders of cerebral circulation reduces the severity of neurological symptoms, increases tissue resistance to hypoxia and ischemia.
It has retinoprotective properties, protects the retina from the damaging effects of high-intensity light, promotes resorption of intraocular hemorrhages, improves eye microcirculation.
Indications
Subconjunctival and intraocular hemorrhage, angioretinopathy (including diabetic), chorioretinal dystrophy (including atherosclerotic origin), dystrophic keratitis, retinal vascular thrombosis, complications of myopia, protection of the cornea (when wearing contact lenses) and the retina from exposure to high-intensity light (laser and sunburn, laser-coagulation), trauma, inflammation and burns of the cornea, cataracts (including prevention in people over 40), surgical interventions in the eyes, the condition after surgery for glaucoma with detachment of the choroid.
Contraindications
Hypersensitivity, pregnancy.
Use during pregnancy and lactation
Contraindicated in pregnancy.
Composition
1 ml of solution contains
Active ingredient: methylethylpyridinol hydrochloride (emoxypine) 10 mg
Dosage and administration
Subconjunctival or parabulbar, 1 time per day or every other day. Subconjunctival – 0.2-0.5 ml of 1% solution (2-5 mg), parabulbar – 0.5-1 ml of 1% solution (5-1 mg). The duration of treatment is 10-30 days, a course may be repeated 2-3 times a year.
Side effects
Short-term agitation, drowsiness, increased blood pressure, allergic reactions (skin rashes, etc.), local reactions – pain, burning, itching, hyperemia, densification of paraorbital tissues (resolves independently).
Drug Interaction
Pharmaceutically not compatible with other medicines.
Storage Conditions
In a dark place. Keep out of reach of children.
Shelf life
3 years.
Deystvuyushtee substance
Metilэtilpiridinol
drugstore conditions
drugstore
dosage form
injection
Prescribing
Prescribing
Adults as prescribed by a doctor
Moscow endocrine another factory, Russia
